New South Park Features A Hilarious Hillbilly Send-Up Of Kendrick Lamar’s “HUMBLE.” [Watch]

first_imgWhile there may be a lot of things wrong with the world we live in today, the new season of South Park just started last night, so thats at least one recent event that we can mark in the “win” column. Known for their bitingly clever satire and absurdist sense of humor, the show has frequently riffed on popular music and artists, from gay fish Kanye West, to the “mysterious” true identity of Lorde, to crunchy “Hippie Jam Fest 2005” headliners Phish.Last night, the show kicked off its 21st (?!) season, and while the kids are still somehow in elementary school decades later, their humor hasn’t lost step with the art of topical humor. In the episode, the main “joke” is that, in order to increase jobs, tasks for which we’ve gotten used to relying on electronics are replaced by actual human laborers. Perpeturally-spoiled and bratty character Eric Cartman learns of this “advancement” when his precious voice-activated “Alexa” device disappears and his mom informs him that she has replaced it with a “Jim Bob.”Watch Kendrick Lamar Perform Fiery Medley Of “HUMBLE.” & “DNA.” At The Video Music Awards“Jim Bob,” it turns out, is a fat redneck wielding a bunch of cell phones and other devices to “replicate” the functions of “Alexa.” As part of demonstrating the abilities of the “Jim Bob,” responds to a command to “Play Kendrick Lamar” with a hilarious twangy southern country reinterpretation of his recent smash hit, “HUMBLE.”You can watch the hillbilly “HUMBLE.” below, via Hulu:For comparison, in case you have been living under a rock since April, here’s the original version of Kendrick Lamar’s “HUMBLE.” for comparison:New episodes of South Park air Wednesday nights on Comedy Central.Kendrick Lamar completed a full-blown national arena tour this summer behind his critically and commercially successful LP, DAMN., and recently won 6 awards at the MTV Video Music Awards, where he performed a medley of two DAMN. tracks complete with flaming ninjas and more pyrotechnic brilliance. The rapper has no tour dates or projects currently announced, but with his recent success, it’s hard to imagine that being the case for too long.[h/t – Pitchfork]last_img read more

Betfair – Le Pen drifts but punters still seek Trump-like moment

first_img With just three days to go until France heads for its final round of General Election voting (Sunday 7 May), Betfair Politics has priced far-right candidate Marie Le Pen at 9/1 (11% chance of winning).Updating its ‘France 2017 market’, Betfair Politics has detailed that yesterday’s live TV debate between Le Pen and Emmanuel Macron favoured the centrist ‘En Marche’ candidate Macron who is currently priced at 1.12 (89% chance of winning).Heading into Sunday’s final ballot, Betfair has traded + £25 million on its market, with Le Pen receiving substantial backing in a ‘two-horse race’. The bookmaker details that a Le Pen victory will be seen as another Trump-like upset, with bookmakers paying out hefty sums to political punters.Commenting on the market, Betfair Spokesperson, Katie Baylis said: “Most political commentators agreed that Macron came out the winner of what proved to be an extremely acrimonious debate and the betting certainly reflected that.“However, overnight backing came for Le Pen who continues to attract far more bets than Macron, in fact 73% of all bets this week have been on her. But unsurprisingly the big money is being staked on Macron, with 90% of money placed on the favourite so far today, including a £50k bet placed this morning.”French Presidential Election 2017Next President – £25m MatchedEmmanuel Macron              1.12 (1/8 or an 89% chance)Marine Le Pen                    9 (8/1 or an 11% chance)Le Pen 2nd Round Vote Percentage30% or lower           42 (41/1)30.01 – 35%            8.8 (8/1)35.01 – 40%            2.44 (6/4)40.01 – 45%            3.2 (11/5)45.01 – 50%            8 (7/1)50.01% or higher      10 (9/1)2nd Round Vote Turnout70% or lower           7 (6/1)70.01 – 73%            5 (4/1)73.01 – 76%            3.8 (14/5)76.01 – 79%            3.75 (11/4)79.01 – 82%            6.8 (6/1)82.01 – 85%            25 (24/1)85.01 – 88%            110 (109/1)88.01% or higher      250 (249/1) StumbleUpon Betfair – Record breaking summer of betting on women’s sports August 3, 2017 Bookmakers shorten Tory odds as Labour comeback fades June 7, 2017 Related Articles Share Share Submit New poll details the changing US sentiment on legalised sports betting September 27, 2017last_img read more

Arsenal blow! January target Jorginho begins new contract talks with Napoli

first_img1 Napoli have opened talks over a new contract with Arsenal target Jorginho.The Brazilian has been heavily linked with a January move to the Emirates in recent months after impressing in Serie A.Arsenal are on the hunt for a defensive midfielder to provide competition for Francis Coquelin and have identified the former Verona man as an ideal addition.However they may now struggle to snap up Jorginho as, according to Sky Italia, Napoli have begun contract talks with the player.The Italian club are desperate to hold onto the 23-year-old and hope that a new deal could persuade him to stay put. Napoli star Jorginho last_img

Common medications sway moral judgment

first_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Email Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe So neuroscientist Molly Crockett of the University of Oxford in the United Kingdom and her colleagues developed a lab test with real consequences. They asked subjects to make a series of decisions about how many moderately painful electric shocks to deliver to themselves or to others. Half the questions gave volunteers a chance to earn money by inflicting self-harm. (For example: “Would you rather endure seven shocks to earn $10 or 10 shocks to earn $15?”) The other half offered the same type of decision, except that someone else stood to be shocked. At the end of the experiment, one of these choices was randomly selected and carried out: The decision-maker got paid, and either they or another person—waiting in a different room—got a series of painful zings on the wrist. Any answer could be the one with real consequences, so “people have to sort of put their money where their mouth is,” Crockett says.The researchers could then calculate the “exchange rate between money and pain”—how much extra cash a person must be paid to accept one additional shock. In previous research, Crockett’s team learned that the exchange rate varies depending on who gets hurt. On average, people are more reluctant to profit from someone else’s pain than their own—a phenomenon the researchers call “hyperaltruism.”In the new study, the scientists tested whether drugs can shift that pain-to-money exchange rate. A few hours before the test, they gave the subjects either a placebo pill or one of two drugs: the serotonin-enhancing antidepressant drug citalopram or the Parkinson’s treatment levodopa, which increases dopamine levels.On average, people receiving the placebo were willing to forfeit about 55 cents per shock to avoid harming themselves, and 69 cents to avoid harming others. Those amounts nearly doubled in people who took citalopram: They were generally more averse to causing harm, but still preferred profiting from their own pain over another’s, Crockett’s team reports online today in Current Biology. Levodopa had a different effect: It seemed to make people just as willing to shock others as themselves for profit.The design of the study is “something that the field of aggression needed for a really long time,” says Joshua Buckholtz, an experimental psychologist at Harvard University. The results, he says, separate out two distinct components that drive our social behavior: the way we conceive of harm to others and our preference for enduring harm rather than inflicting it. The dopamine drug—but not the serotonin drug—seemed to change that preference.Crockett says those effects could suggests multiple underlying mechanisms. For example, excess dopamine might make our brain’s reward system more responsive to the prospect of avoiding personal harm. Or it could tamp down our sense of uncertainty about what another person is experiencing, making us less hesitant to dole out pain. Serotonin, meanwhile, appeared to have a more general effect on aversion to harm, not just a heightened concern for another person. Such knowledge could eventually develop drugs that address disorders of social behavior, she says.Still, the study did not measure levels of dopamine or serotonin in the brain to confirm that they were elevated while the subjects were taking the test, notes Jay Gingrich, a developmental neurobiologist at the Columbia University Medical Center. He questions whether a single dose of citalopram can reliably increase serotonin levels just a few hours later. “Maybe they’re onto something,” he says, “but my big concern was them over-interpreting what the pharmacology was doing.”Crockett says she relied on past research to identify the point at which absorption of the drugs was highest, but she couldn’t confirm neurotransmitter levels for sure without a more invasive test, such as a PET scan.She is also careful to point out that the two drugs—administered only to healthy volunteers in the study—are likely to have different effects on social behavior in people taking them to treat an illness. For example, in Parkinson’s patients who are deficient in dopamine, the drug may simply restore normal levels, not create an undesirable surplus, she says. “The last thing I want is for people who are taking these drugs for medical reasons to become concerned about the implications of this study for their own decision-making.”center_img Click to view the privacy policy. Required fields are indicated by an asterisk (*) How many times would you give your neighbor an electric shock to earn a few extra bucks? Your answer could be more malleable than you think. A new study finds that two common drugs—an antidepressant and a treatment for Parkinson’s disease—can influence moral decisions, a discovery that could help unravel specific mechanisms behind aggression and eventually help researchers design treatments for antisocial behavior.Previous research has linked two neurotransmitters, the brain’s signaling molecules, to our willingness to inflict harm. Serotonin appears to help keep us civil; it’s reduced in the brains of violent offenders, for example. Dopamine, meanwhile, has been shown to prompt aggression in animals, and it’s elevated in a certain part of the brain in people with psychopathic behavior.But measuring how these neurotransmitters contribute to moral decision-making is hard to do in the lab. Many studies rely on theoretical questions like the so-called trolley dilemma, which asks a person whether they would redirect an oncoming train to kill someone if it would save the lives of several others in its path. A person’s answer might not always reflect how they would behave in real life, however.last_img read more